Holen Sie sich die Stockscreener-App
2.415
3.63%
0.075
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story - Yahoo Finance
Ocugen (OCGN) Valuation Update As Phase 3 OCU400 Enrollment Completes And Going Concern Risks Persist - simplywall.st
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making - AOL.com
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen (OCGN) Surges to 52-Week High on Oppenheimer's Outperform Rating - GuruFocus
Investors Buy Large Volume of Ocugen Call Options (NASDAQ:OCGN) - MarketBeat
Ocugen stock wins new Outperform at Oppenheimer (OCGN:NASDAQ) - Seeking Alpha
Ocugen (NASDAQ:OCGN) Hits New 12-Month HighWhat's Next? - MarketBeat
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline - AOL.com
OCGN: Oppenheimer Initiates Coverage with Outperform Rating | OC - GuruFocus
HC Wainwright Brokers Increase Earnings Estimates for Ocugen - MarketBeat
Oppenheimer Initiates Ocugen at Outperform With $10 Price Target - marketscreener.com
Oppenheimer initiates Ocugen stock rating at Outperform on gene therapy potential - Investing.com
Ocugen price target raised to $22 from $15 at Lucid Capital - TipRanks
Ocugen's Clinical Ambition Meets Market Skepticism - AD HOC NEWS
Ocugen’s Gene Therapy Pipeline Dominates Earnings Call - TipRanks
Ocugen Faces Analyst Scrutiny Despite Pipeline Progress - AD HOC NEWS
Ocugen Reports 2025 Results and Clinical Progress Across Gene Therapy Pipeline - MyChesCo
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo! Finance Canada
FY2030 Earnings Forecast for Ocugen Issued By HC Wainwright - MarketBeat
Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy - MyChesCo
Ocugen: Downgrade "Hold" After OCU410 Data Release (NASDAQ:OCGN) - Seeking Alpha
312,319,623 Common Stock of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Ocugen, Inc. honors women leaders advancing gene therapy innovation - Traders Union
Is Ocugen Inc. (2H51) stock worth buying before Fed actionInsider Selling & Free High Return Stock Watch Alerts - Naître et grandir
Will Ocugen Inc. stock continue upward momentumTrade Exit Report & AI Optimized Trade Strategies - Naître et grandir
Ocugen (NASDAQ:OCGN) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Employee dedication drives gene therapy progress, Ocugen, Inc. asserts - Traders Union
Ocugen’s Growing Pains: High Execution and Compliance Risks Threaten Shareholder Value - TipRanks
Ocugen (NASDAQ:OCGN) Trading Down 7.2%Here's Why - MarketBeat
OCGN Analyst Rating Maintained by Chardan Capital at Buy with $7 - GuruFocus
Ocugen (NASDAQ:OCGN) Receives "Buy" Rating from Chardan Capital - MarketBeat
Ocugen, Inc. Hits New 52-Week High of $2.00, Marking Major Milestone - Markets Mojo
Ocugen, Inc. (NASDAQ:OCGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Ocugen Posts Wider FY25 Loss, Advances Gene Therapy And Vaccine Pipeline - Nasdaq
Ocugen Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com South Africa
Ocugen 2025 Financial Results: Quarterly and Annual ReportNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Ocugen (OCGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com Nigeria
Ocugen (OCGN) Advances Gene Therapy Trials and Strengthens Leade - GuruFocus
Ocugen (NASDAQ:OCGN) Shares Gap DownWhat's Next? - MarketBeat
Ocugen (OCGN) Reports Q4 Earnings and Cash Position Update - GuruFocus
Ocugen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - Ocugen, Inc.
Ocugen 10-K: Revenue $4.4M, Net Loss $67.8M - TradingView
Ocugen (NASDAQ: OCGN) advances RP, GA and Stargardt gene therapies - Stock Titan
Ocugen Seeks Court Validation of Charter Amendment Dispute - TipRanks
Ocugen (NASDAQ:OCGN) Announces Earnings Results - MarketBeat
Court petition over Ocugen (NASDAQ: OCGN) share increase vote - Stock Titan
Ocugen (NASDAQ: OCGN) advances eye gene therapies and extends cash runway - Stock Titan
Ocugen, Inc. completes OCU400 Phase 3 and secures first OCU400 licensing deal amid leadership boost - Traders Union
Ocugen Q4 Earnings Call Highlights - MarketBeat
OCGN: Advanced gene therapy pipeline, strong clinical data, and extended cash runway into late 2026 - TradingView
Ocugen reports Q4 EPS (6c), consensus (6c) - TipRanks
OCGN: OCU400 Phase 3 enrollment completed; strong pipeline progress and extended cash runway - TradingView
Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ocugen (OCGN) Achieves Significant Milestones in 2025 - GuruFocus
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):